Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Multiple Myeloma through trial conditions or approval indications mapped to it or to one of its descendant entities.
6 drugs · 36 active trials
25 drugs · 1,009 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 12 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Perifosine | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2005-12 |
| Prednisolone | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2008-07 |
| Masitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2005-02 |
| Tanespimycin | Phase 3 | Phase 3 | 0 | 0 | 2 | 2 | 0 | — | — | 2007-08 |
| Ibandronic Acid | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2006-02 |
| Nirogacestat | Phase 2 | Phase 2 | 8 | 2 | 0 | 10 | 0 | — | — | Sep 23, 2019 |
| Crizotinib | Phase 2 | Phase 2 | 6 | 1 | 0 | 6 | 0 | — | — | Aug 12, 2015 |
| Ruxolitinib | Phase 2 | Phase 2 | 4 | 4 | 0 | 7 | 0 | — | — | 2008-03 |
| Sunitinib | Phase 2 | Phase 2 | 4 | 2 | 0 | 7 | 0 | — | — | 2007-09 |
| Thiotepa | Phase 2 | Phase 2 | 3 | 0 | 0 | 9 | 0 | — | — | Nov 18, 2005 |
| Aldesleukin | Phase 2 | Phase 2 | 3 | 3 | 0 | 7 | 0 | — | — | 1996-03 |
| Vismodegib | Phase 2 | Phase 2 | 3 | 1 | 0 | 5 | 0 | — | — | 2010-12 |
| Afatinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | Aug 12, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Sapanisertib | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | 2010-11 |
| Cemiplimab | Phase 2 | Phase 2 | 3 | 2 | 0 | 3 | 0 | — | — | Apr 4, 2017 |
| Azacitidine | Phase 2 | Phase 2 | 2 | 2 | 0 | 12 | 0 | — | — | 2006-12 |
| Palbociclib | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | 2008-01 |
| Binimetinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Olaparib | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Mar 14, 2016 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Aug 12, 2015 |
| Adavosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ipatasertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Osimertinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Taselisib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Rituximab | Phase 2 | Phase 2 | 1 | 1 | 0 | 11 | 0 | — | — | 2002-01 |
| Tretinoin | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2013-12 |
| Temsirolimus | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2004-02 |
| Metformin | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2017-01 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 14, 2016 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Oct 7, 2019 |
| Erlotinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 23, 2018 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Leuprolide | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2011-07 |
| Paclitaxel | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2014-01 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Feb 27, 2015 |
| Treosulfan | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2005-09 |
| Axitinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 23, 2018 |
| Bosutinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 23, 2018 |
| Dabrafenib/Trametinib Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 14, 2016 |
| Degarelix | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2012-12 |
| Epirubicin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 20, 2023 |
| Futibatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 14, 2016 |
| Gilteritinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 28, 2022 |
| Radiation Therapy | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 31, 2022 |
| Talazoparib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 14, 2016 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.